A 3-Year-Old's Metastatic Cancer Vanished After Two Doses of Experimental Therapy
AI Image

A 3-Year-Old's Metastatic Cancer Vanished After Two Doses of Experimental Therapy

Yahoo • • health

Key Points:

  • A three-year-old boy with chemotherapy-resistant hepatoblastoma, a malignant liver cancer, achieved complete tumor regression after receiving experimental CAR T cell therapy targeting glypican-3 (GPC3).
  • The therapy involved genetically engineered T cells designed to enhance longevity and tumor-killing ability by expressing immune proteins interleukin-15 and interleukin-21.
  • Following two infusions of the GPC3-CAR treatment, the patient showed no signs of cancer after 12 months, marking a significant breakthrough in treating solid tumors with CAR T cell therapy.
  • This case, published in The New England Journal of Medicine, suggests potential for CAR T cell therapy to be a safe and effective treatment for GPC3-positive solid tumors, including liver cancer, which is a leading cause of cancer-related deaths worldwide.
  • Further clinical trials, including the ongoing CARE and IMPACT studies, are necessary to evaluate the broader efficacy and safety of this treatment in more patients.

Trending Business

Trending Technology

Trending Health